159 related articles for article (PubMed ID: 28055196)
1. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
3. Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.
Kumar J; Umar T; Kausar T; Mobashir M; Nayeem SM; Hoda N
J Mol Model; 2017 Jan; 23(1):7. PubMed ID: 27966018
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
[TBL] [Abstract][Full Text] [Related]
5. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
[TBL] [Abstract][Full Text] [Related]
6. [1,2,4]Triazolo[1,5-
Tresadern G; Velter I; Trabanco AA; Van den Keybus F; Macdonald GJ; Somers MVF; Vanhoof G; Leonard PM; Lamers MBAC; Van Roosbroeck YEM; Buijnsters PJJA
J Med Chem; 2020 Nov; 63(21):12887-12910. PubMed ID: 33105987
[TBL] [Abstract][Full Text] [Related]
7. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
[TBL] [Abstract][Full Text] [Related]
8. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Gangwal RP; Damre MV; Das NR; Dhoke GV; Bhadauriya A; Varikoti RA; Sharma SS; Sangamwar AT
J Mol Graph Model; 2015 Apr; 57():89-98. PubMed ID: 25687765
[TBL] [Abstract][Full Text] [Related]
9. Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).
Trabanco AA; Buijnsters P; Rombouts FJ
Expert Opin Ther Pat; 2016 Aug; 26(8):933-46. PubMed ID: 27321640
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.
Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB
J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
[TBL] [Abstract][Full Text] [Related]
12. A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
Wunder F; Gnoth MJ; Geerts A; Barufe D
Mol Pharm; 2009; 6(1):326-36. PubMed ID: 19049345
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Egerland U; Kranz M; Scheunemann M; Höfgen N; Steinbach J; Brust P
Molecules; 2015 May; 20(6):9591-615. PubMed ID: 26016549
[TBL] [Abstract][Full Text] [Related]
14. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
Hamza A; Zhan CG
J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into selective phosphodiesterase 4B inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sharma V; Wakode S
J Biomol Struct Dyn; 2017 May; 35(6):1339-1349. PubMed ID: 27136969
[No Abstract] [Full Text] [Related]
16. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
17. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
Chen CY
J Biomol Struct Dyn; 2010 Apr; 27(5):627-40. PubMed ID: 20085380
[TBL] [Abstract][Full Text] [Related]
19. Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
Jiang MY; Han C; Zhang C; Zhou Q; Zhang B; Le ML; Huang MX; Wu Y; Luo HB
Bioorg Med Chem Lett; 2021 Jun; 41():128016. PubMed ID: 33838306
[TBL] [Abstract][Full Text] [Related]
20. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
